All In Biotech

Drug Trial Radar · NCT04193527

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls

Last checked: Nov 20, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Jun 28, 2020

Primary completion

Dec 20, 2021

Study completion Dec 20, 2021

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Dec 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of Parkinsonian syndrome (PS) involving striatal dopaminergic deficit (SDD; specifically, Parkinson's disease \[PD\] \[SDD\], multiple system atrophy \[MSA\] \[SDD\] or or progressive supranuclear palsy \[PSP\] \[SDD\]) as compared with patients with a clinical diagnosis of essential tremor (ET) (no SDD) and age-matched healthy controls.

Conditions

  • Parkinsonian Syndrome
  • Parkinson Disease(PD)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Essential Tremor

Interventions

  • DaTSCAN™ Ioflupane (123I) InjectionDrug

    All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT ImagesTime frame: At Day 1
  2. Specificity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT ImagesTime frame: At Day 1

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

  • Beijing Friendship Hospital Afflication to Capital Medical University

    Beijing, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • Tianjin Medical University General Hospital

    Tianjin, China

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Chaoyang District, China

  • Peking Union Medical College Hospital

    Beijing, Dongcheng District, China

  • Nanfang Hospital, Nanfang Medical Univeristy

    Guangdong, Guangzhou, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • The Second Affilicated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Shanghai General Hospital

    Hongkou, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.